使用微创细胞采样装置筛查胃食管反流病患者巴雷特食管的成本效益分析
该研究将Cytosponge性能的临床试验数据纳入两个经验证的食管腺癌微模拟模型,模拟60岁男性胃食管反流病患者一次性筛查巴雷特食管的策略。结果显示,Cytosponge联合内镜确认阳性结果的筛查策略较单纯内镜筛查降低筛查成本27%至29%,但每1000例患者减少1.8至5.5个质量调整生命年。Cytosponge筛查相较不筛查的增量成本效果比为26,358至33,307美元。
要点
- Cytosponge联合内镜确认阳性结果筛查巴雷特食管较单纯内镜筛查降低筛查成本27%至29%。
- Cytosponge筛查每1000例患者较内镜筛查减少1.8至5.5个质量调整生命年。
- Cytosponge筛查相较不筛查的增量成本效果比为26,358至33,307美元。
核心结论
- 在胃食管反流病患者巴雷特食管筛查策略的比较模型分析中,Cytosponge筛查联合内镜确认阳性结果是一种具有成本效益的策略。
- 内镜筛查获得的健康获益最大,但成本边际不理想。
研究设计与样本
- 将Cytosponge性能的大型临床试验数据纳入两个经验证的食管腺癌微模拟模型(麻省总医院食管腺癌模型和伊拉斯谟大学医学中心微模拟筛查分析模型)。
- 模型依据美国监测、流行病学和最终结果(SEER)数据库中食管腺癌发病率和死亡率数据进行校准。
- 在每个模型中模拟60岁男性胃食管反流病患者一次性筛查巴雷特食管的策略:单纯内镜筛查,或Cytosponge采集组织并检测三叶因子3水平后对内镜确认阳性结果者进行确认。
- 记录每个策略下食管腺癌发生例数、经Cytosponge筛查或后续针对性监测发现的食管腺癌例数以及所需内镜数量。
- 记录每个策略的累积成本(包括间接成本)和质量调整生命年,按每年3%的贴现率贴现,并计算三种策略间的增量成本效果比(ICER)。
主要发现
- Cytosponge筛查联合内镜确认阳性结果较内镜筛查降低筛查成本27%至29%。
- Cytosponge筛查联合内镜确认阳性结果较内镜筛查每1000例患者减少1.8至5.5个质量调整生命年。
- Cytosponge筛查相较不筛查的ICER为26,358至33,307美元。
- 内镜筛查相较Cytosponge筛查的ICER为107,583至330,361美元。
- 上述结果对合理范围内的Cytosponge成本敏感。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is important to identify patients with Barrett's esophagus (BE), the precursor to esophageal adenocarcinoma (EAC). Patients with BE usually are identified by endoscopy, which is expensive. The Cytosponge, which collects tissue from the esophagus noninvasively, could be a cost-effective tool for screening individuals with gastroesophageal reflux disease (GERD) who are at increased risk for BE. We developed a model to analyze the cost effectiveness of using the Cytosponge in first-line screening of patients with GERD for BE with endoscopic confirmation, compared with endoscopy screening only. METHODS: We incorporated data from a large clinical trial of Cytosponge performance into 2 validated microsimulation models of EAC progression (the esophageal adenocarcinoma model from Massachusetts General Hospital and the microsimulation screening analysis model from Erasmus University Medical Center). The models were calibrated for US Surveillance, Epidemiology and End Results data on EAC incidence and mortality. In each model, we simulated the effect of a 1-time screen for BE in male patients with GERD, 60 years of age, using endoscopy alone or Cytosponge collection of tissue, and analysis for the level of trefoil factor 3 with endoscopic confirmation of positive results. For each strategy we recorded the number of cases of EAC that developed, the number of EAC cases detected with screening by Cytosponge only or by subsequent targeted surveillance, and the number of endoscopies needed. In addition, we recorded the cumulative costs (including indirect costs) incurred and quality-adjusted years of life lived within each strategy, discounted at a rate of 3% per year, and computed incremental cost-effectiveness ratios (ICERs) among the 3 strategies. RESULTS: According to the models, screening patients with GERD by Cytosponge with follow-up confirmation of positive results by endoscopy would reduce the cost of screening by 27% to 29% compared with screening by endoscopy, but led to 1.8 to 5.5 (per 1000 patients) fewer quality-adjusted life years. The ICERs for Cytosponge screening compared with no screening ranged from $26,358 to $33,307. For screening patients by endoscopy compared with Cytosponge the ICERs ranged from $107,583 to $330,361. These results were sensitive to Cytosponge cost within a plausible range of values. CONCLUSIONS: In a comparative modeling analysis of screening strategies for BE in patients with GERD, we found Cytosponge screening with endoscopic confirmation to be a cost-effective strategy. The greatest benefit was achieved by endoscopic screening, but with an unfavorable cost margin.
引用
- Heberle CR, Omidvari AH, Ali A, et al. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017. PMID: 28238953. doi:10.1016/j.cgh.2017.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。